PharmaTelevision - Takeda Research Investment: Reaching Beyond the Land of the Rising Sun

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Takeda Research Investment: Reaching Beyond the Land of the Rising Sun

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

This insightful conversation features Graeme Martin, CEO of Takeda Research Investment (TRI) the corporate venture arm of Takeda Pharmaceutical, the largest pharma company in Japan and among the largest in the world. Dr. Martin shares TRI’s plans to invest US$100 million seed money in a variety of early-stage innovative ventures, to help expand Takeda’s research horizons outside Japan. With a plan to invest in 4-5 new efforts a year, TRI hopes to eventually manage a steady state investment of about 20 companies that will include both minority investments and active, collaborative partnerships designed to create synergies with Takeda’s considerable R&D resources.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The purpose of setting up Takeda Research Investment.

Fintan Walton:

Hello and welcome to PharmaTelevision, the world's first pharmaceutical on demand television channel. We are here in Madrid recording a series of interviews with some of the leading pharmaceutical and biotechnology companies who are presenting here at Bio Europe. We hope you enjoy these shows. Hello and welcome to PharmaVentures business review here in Madrid. On this show I have Graeme Martin, who is President and CEO of Takeda Research Investment. Welcome to the show.

Graeme Martin:

Thank you.

Fintan Walton:

Graeme Martin, Takeda Research Investment is based in Palo Alto as I said it's part of Takeda the famous Japanese multinational pharmaceutical company, what is the purpose of Takeda Research Investment?

Graeme Martin:

Takeda set up Takeda Research Investment 2001 and so it's been running for just a little over seven-years now. And the purpose was to help Japan's research centre expand it's horizons outside Japan specifically in North America and in Europe. So we were looking as eyes and ears for research division to bring in innovation into, into the research group.

Fintan Walton:

And why are you actually based in Palo Alto, does that mean you are just focused purely in California are you looking outside of California as well?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Graeme Martin

President and Chief Executive Officer

Dr Graeme Martin is President and CEO of TRI with day-to-day responsibility for operations. He brings more than 28 years of pharmaceutical R&D experience, primarily in multinational Pharmas (Wellcome; Glaxo Wellcome: Hoffman La Roche). He was responsible for the discovery and preclinical development of Zomig, marketed worldwide for the acute treatment of migraine. More recently, Dr. Graeme Martin served as Chief Technical Officer at Telik Inc.with responsibility for technology and business development before establishing a Bay Area biopharmaceutical consulting operation, Discovery-Insight. Dr. Graeme Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK.

Takeda Research Investment

Takeda Research Investment, Inc. (TRI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. A wholly-owned subsidiary of Takeda America Holdings, Inc, TRI started operations in 2002. Their aim is to encourage and support therapeutic innovation in biopharmaceutical companies and academic centre's of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.